A new study from UCLA Health researchers demonstrates that a novel treatment is effective in most patients with major depressive symptoms even after multiple failed courses of antidepressant medication.
Menu
Top of the morning to you and a fine one it is. Despite cloudy skies hovering over the Pharmalot campus, our spirits remain sunny. How
The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to compete with the newly-approved Cobenfy from Bristol Myers Squibb